http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022132894-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82a308524dd92f08d281d392c66fe6f7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-235 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-235 |
| filingDate | 2021-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4c26e7193b49fa90d63876ebbbde168 |
| publicationDate | 2022-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022132894-A1 |
| titleOfInvention | Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders |
| abstract | The present disclosure generally relates to This disclosure relates to pharmaceutical compositions useful for inhibiting the progression of urea cycle disorders and neurodegenerative disorders, such as Huntington's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis. The pharmaceutical compositions may include glycerol tribenzoate and glycerol phenylbutyrate. The pharmaceutical compositions may be administered to the patient in any suitable manner, such as intranasally or orally. |
| priorityDate | 2020-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1271.